Clinical trial
Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
NCT00113230 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00113230 |
|---|---|
| Title | Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer |
| Official title | Phase II Trial Of Neoadjuvant Concurrent Capecitabine, RHUMAB VEGF (Avastin) And Radiotherapy In Patients Presenting With Locally Advanced Rectal Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rectal Cancer |
| Intervention type | Drug, Radiation |
| Interventions | Avastin (Bevacizumab, RHUMAB VEGF), Capecitabine, Radiation Therapy |
| Enrollment | 25 |
| Start date | Feb 1, 2005 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Jun 7, 2005 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: